The IDKmonitor® Infliximab Total ADA ELISA (Health Canada) is intended for the determination of human antibodies against TNFα blocker infliximab (e.g. REMICADE®) in the presence of infliximab in EDTA plasma and serum.
Health Canada Licensed.
For Laboratory Professional Use Only.
Not for sale in the U.S. Please contact us to order or get a quote.
If you’re in the U.S., we offer an RUO version of this kit: KR9654
Manufactured by Immundiagnostik AG.
Also available:
This test is for the determination of antibodies against TNFα-Blocker infliximab (e. g. REMICADE®).
During sample preparation, the anti-drug antibodies (ADA) are separated from the therapeutic antibody to acquire free ADA. By adding the conjugate (peroxidase-labeled therapeutic antibody) and the tracer (biotinylated therapeutic antibody), the unmarked therapeutic antibodies are replaced, and the marked antibodies can form a complex with the ADA. This complex binds via biotin to the streptavidin-coated microtiter plate. It is detected via the peroxidase conjugate with the peroxidase converting the substrate TMB to a blue product.
Adding an acidic solution stops the enzymatic reaction. The samples convert from blue to yellow. The color change should be measured in a photometer at 450 nm. The interpretation is made using the cut-off control.
